{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-135328","form_type":"8-K","ticker":"RXST","cik":"0001111485","company_name":"RxSight, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.331617+00:00","generated_at":"2026-06-02T04:50:34.622092+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"RxSight prices $100M public stock offering at $56/share for commercial expansion","bullets":["Offering of 1,785,714 shares at $56/share; underwriters have 30-day option for 267,857 additional shares.","Net proceeds expected ~$93.2M after underwriting discount and estimated offering expenses.","Proceeds to fund commercial/marketing expansion (including international), product development, R&D, and working capital.","Offering expected to close May 13, 2024, subject to customary closing conditions.","Directors and executive officers subject to 60-day lock-up restrictions on their shares."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-135328","json":"https://secwatch.observer/filing/0001193125-24-135328.json","markdown":"https://secwatch.observer/filing/0001193125-24-135328.md","text":"https://secwatch.observer/filing/0001193125-24-135328.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1111485/000119312524135328/0001193125-24-135328-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1111485/000119312524135328/d832746d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T04:50:34.622092+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1f0ccdf5d01d11913e94538dc02f45e4d46fc673","claim":"RxSight, Inc. entered into Underwriting Agreement with BofA Securities, Inc., as representative of the several underwriters listed in Schedule 1 thereto (the \"Underwriters\") valued at approximately $93.2 million (effective 2024-05-08).","evidence_excerpt":"On May 8, 2024, RxSight, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with BofA Securities, Inc., as representative of the several underwriters listed in Schedule 1 thereto (the “Underwriters”), pursuant to which the Company agreed to issue and sell 1,785,714 shares (the “Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1111485/000119312524135328/0001193125-24-135328-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"BofA Securities, Inc., as representative of the several underwriters listed in Schedule 1 thereto (the \"Underwriters\")"},{"label":"Value","value":"approximately $93.2 million"},{"label":"Effective","value":"2024-05-08"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}